ASAP Stock Overview
Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Asarina Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.95 |
| 52 Week High | kr1.63 |
| 52 Week Low | kr0.60 |
| Beta | 0.41 |
| 1 Month Change | 2.14% |
| 3 Month Change | -10.00% |
| 1 Year Change | -19.15% |
| 3 Year Change | -85.72% |
| 5 Year Change | -96.54% |
| Change since IPO | -97.44% |
Recent News & Updates
Shareholder Returns
| ASAP | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 5.5% | -4.9% | -0.7% |
| 1Y | -19.2% | 63.3% | 8.8% |
Return vs Industry: ASAP underperformed the Swedish Pharmaceuticals industry which returned 63.3% over the past year.
Return vs Market: ASAP underperformed the Swedish Market which returned 8.8% over the past year.
Price Volatility
| ASAP volatility | |
|---|---|
| ASAP Average Weekly Movement | 11.1% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: ASAP's share price has been volatile over the past 3 months.
Volatility Over Time: ASAP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1 | Peter Nordkild | www.asarinapharma.com |
Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products. Its flagship product is Sepranolone, which is used for the treatment of menstrual migraine and Tourette syndrome. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016.
Asarina Pharma AB (publ) Fundamentals Summary
| ASAP fundamental statistics | |
|---|---|
| Market cap | kr21.60m |
| Earnings (TTM) | -kr12.91m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs ASAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASAP income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr12.91m |
| Earnings | -kr12.91m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 23, 2024
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 64.0% |
How did ASAP perform over the long term?
See historical performance and comparison